Key Takeaways
- Shares surged 28.63% today, a powerful move that puts the stock firmly on investors’ radar.
- Momentum is broad-based, with gains of roughly 30% over the past week and past four weeks, signaling sustained buying interest.
- The company now carries a $15.44 billion market cap, reflecting growing confidence in its long-term potential within the biotech sector.
- Even after the rally, the stock is still below its $105 52-week high, leaving room for further upside while underscoring the volatility typical of biotech names.
Revolution Medicines Inc
RVMD
Price
$102.710000
Last Trading Day
2026-01-07
Open
$80.950000
High
$105.000000
Low
$79.940000
Close
$79.850000
Weekly Close (Adj)
$102.710000
Weekly Change
$23.690000
29.979752%
4W Momentum
30.144450%
52W Range
$31.320000 – $102.710000
Volatility (12W)
8.688466%
Revolution Medicines Inc is a biotechnology company operating within the healthcare sector. It has a market capitalization of $15.44 billion. Currently, there is no P/E ratio available for the company.
Today, the stock price increased by $22.86, representing a rise of 28.63%. Over the past week, the stock has gained approximately 29.98%. In the last four weeks, the momentum has been positive at around 30.14%. The stock has traded within a 52-week range of $31.32 to $102.71.
Why Revolution Medicines Jumped ~29%
- Takeover Rumor Sparked a Rally: Shares jumped sharply after The Wall Street Journal and multiple outlets reported that AbbVie was in advanced talks to acquire Revolution Medicines, potentially valuing the company at around $20 billion — well above its ~$15.4 billion market cap. That buyout speculation drove strong buying pressure. Yahoo Finance+1
- Broader Biotech Strength: The acquisition chatter lifted several oncology biotech stocks alongside RVMD, indicating sector-wide optimism tied to cancer-drug development themes. Yahoo Finance
- Pipeline Progress & Investor Sentiment: Longer-term investor confidence is anchored in Revolution’s targeted cancer therapies and positive clinical/regulatory developments, which have helped the stock trend upward before this spike. AInvest
- Volatility From Conflicting News: After the initial surge, AbbVie denied the takeover talks, which caused a pullback in after-hours trading — highlighting how sensitive RVMD’s price is to news flow. swikblog.com